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tence and increased health care costs in older adults with demen-
tia in a managed care setting. Health status assessments
completed at enrollment had the potential to identify enrollees at
higher risk for nonadherent behaviors and poor health related
outcomes.
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OBJECTIVE: To evaluate the effectiveness of risperidone
long-acting injection (RLAI) treatment on personal and social
functioning in patients with schizophrenia enrolled in the
electronic-Schizophrenia Treatment Adherence Registry (e-
STAR) from six countries (Canada, Czech Republic, Denmark,
Netherlands, Slovakia, Sweden) that collected Personal and
Social Performance (PSP) data. METHODS: e-STAR is an inter-
national, long-term, prospective, observational study of patients
with schizophrenia who commence RLAI. Data are collected
retrospectively for one year and prospectively every three months
for two years. Personal and social functioning is measured using
the PSP scale which evaluates four areas, socially useful activities,
personal and social relationships, self-care, and disturbing and
aggressive behaviour. Pooled results presented are based on data
from patients who have completed their six-month follow-up
visit. RESULTS: To date, 1831 are enrolled in e-STAR from
the six countries, 1232 patients who have been followed for at
least 6 months are included in this analysis. Mean age was
38.4  12.5 years, 58.6% were male and mean time since diag-
nosis was 9.6  11.6 years. At 6 months, 95.5% of patients are
still on RLAI. The mean PSP score signiﬁcantly improved from
48.0  17.3 at baseline to 64.2  15.2 at 6 months (p < 0.001).
Improvement in PSP was similar for patients hospitalized at
baseline versus those who were ambulatory patients (PSP score
increased by 17.2 and 16.1, respectively, p < 0.001 for both).
Furthermore, signiﬁcant improvement in PSP was seen as soon as
the ﬁrst assessment after RLAI treatment at three months. CON-
CLUSION: These 6-month interim results indicate that personal
and social functioning as measured by the PSP improved with
risperidone long-acting injection treatment in patients with
schizophrenia.
PMH59
HEALTH RELATED QUALITY OF LIFE IN PATIENTSTREATED
WITH ANTIPSYCHOTIC DRUGS: RESULTS AT BASELINE FROM
THE COMETA STUDY
Scalone L1, Mantovani LG2, Ferrarini L3, Mencacci C4, Pirfo E5,
Bernareggi M6, Giustra MG6, Berto P7, Sturkenboom MC8
1Centre of Pharmacoeconomics, Milan, Italy, 2University of Naples,
Federico II, Naples, Italy, 3Mental Health Department ASL 3, Genova,
NA, Italy, 4Mental Health Department, Milan, NA, Italy, 5Mental Health
Department G. Maccacaro,Torino, NA, Italy, 6Janssen-Cilag SpA,
Cologno Monzese, Milan, NA, Italy, 7PBE Consulting,Verona, Italy,
8Erasmus University Medical Center, Soest, Netherlands
OBJECTIVE: To measure adherence and persistence in patients
undergoing antipsychotic treatment and their impact on costs
and health-related quality-of-life (HRQoL). METHODS: A
naturalistic, prospective, multicentre cohort study, named
COMETA, was begun in subjects aged 18–40 years, diagnosed
with schizophrenia or schizophreniform disorder 10 years before
the enrolment. Subjects were enrolled and observed for up to
52 weeks in psychiatric centres throughout Italy. Socio-
demographic, clinical, HRQoL and data on resource use were
collected. RESULTS: Six-hundred-sixty-one patients (mean age
31.1 + 5.6, 65.4% male) with schizophrenia (86.5%) or schizo-
phreniform disorder (13.5%) were enrolled in 86 centres during
2006–2007. Most patients had primary/lower secondary level
education (51.9%), and were single (85.9%). A total of 56.6% of
the subjects received help for their disease from relatives/friends,
37.3% of patients were employed, 10.3% were students. The
PANSS (Positive and Negative Syndrome Scale) mean + SD score
was 86.1 + 27.4. The CGI-S (Clinical Global Impression Sever-
ity) mean + SD score was 4.27 + 1.1, the GAF (Global Assess-
ment of Functioning) mean + SD score was 54.3 + 13.8. Ninety
days prior, patients were treated with olanzapine (32.5%), ris-
peridone (31.5%), haloperidol (18.3%), aripiprazole (14.4%),
quetiapine (12.4%) and clozapine (11.2%). Thirty percent of the
patients took >2 different drugs (up to 5) in that period. Regard-
ing HRQoL, 68.7% of patients reported problems on the
anxiety/depression-domain of the EQ-5D, 52.3% on usual activi-
ties, 37.7% on pain/discomfort, 21.4% on mobility and 16.8%
on self-care. The EQ-5D Visual Analogue Scale score was
63.6 + 17.8 (mean + SD). The SF-36 Physical-Summary-Score
was 47.3  9.4 and the Mental Summary Score was 39.0  9.6.
CONCLUSION: Improvement of patients’ well-being is an
important objective of antipsychotic treatment. Baseline charac-
teristics of this schizophrenic cohort show that there is ample
space for improvement. Future analyses will focus on the rela-
tionship between adherence with therapy, symptomatology,
costs, and quality of life.
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OBJECTIVE: To determine the association between various
levels of comorbid anxiety and depression with health-related
quality of life and work-performance. METHODS: Patients from
an anxiety disorders program clinic completed the SF-36, Work
Limitations Questionnaire, Work Productivity and Activity
Impairment Questionnaire, Endicott Work Productivity Scale,
and Work Performance Scale. The Beck Anxiety Inventory (BAI)
and the Beck Depression Inventory (BDI) were used to determine
the severity of anxiety and depression, respectively. Patients were
categorized as lowBAI/lowBDI, highBAI/lowBDI, highBAI/
lowBDI, and highBAI/highBDI. The inﬂuence of severity of
anxiety/depression on the eight SF-36 scales, the SF-36 PCS and
MCS, and each work-performance instrument scale score was
determined using ANOVA with Scheffe post-hoc analyses. Mul-
tivariate linear regression assessed the combined association of
BAI and BDI on SF-36 and work-performance scales, controlling
for patient demographics. P values of <0.05 were statistically
signiﬁcant. RESULTS: Ninety-one patients provided complete
SF-36, BAI and BDI. Of these, 61 were employed. There were no
differences in demographics between groups. Post-hoc analy-
sis indicated that lowBAI/lowBDI patients had signiﬁcantly
higher MCS (41.2 + 10.9) compared to highBAI/lowBDI
(MCS = 29.9 + 8.3), lowBAI/highBDI (MCS = 23.7 + 15.8),
and highBAI/highBDI (MCS = 17.4 + 9.9). The difference
between highBAI/lowBDI and lowBAI/highBDI were not signiﬁ-
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